Testing effectiveness (Phase 2)Study completedNCT00524277What this trial is testingVaccine Therapy in Treating Patients With Breast CancerWho this might be right forBreast Cancer San Antonio Military Medical Center 456
Not applicableStudy completedNCT04276272What this trial is testingD4 Choline Breast PET/CTWho this might be right forHER2-negative Breast CancerER Positive Breast CancerMetastatic Breast Cancer Imperial College London 6
Testing effectiveness (Phase 2)Study completedNCT01142778What this trial is testingBevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 152
Large-scale testing (Phase 3)Active Not RecruitingNCT04055493What this trial is testingAdj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCWho this might be right forBreast Cancer Female Women's Cancer Study Group GmbH 1,684
Not applicableActive Not RecruitingNCT07342309What this trial is testingReal-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United StatesWho this might be right forMetastatic Breast Cancer Boehringer Ingelheim 7,933
Early research (Phase 1)Looking for participantsNCT07361562What this trial is testingA Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more Cogent Biosciences, Inc. 100
Early research (Phase 1)Looking for participantsNCT06253871What this trial is testingA Phase 1/1b Study of IAM1363 in HER2 CancersWho this might be right forHER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more Iambic Therapeutics, Inc 383
Testing effectiveness (Phase 2)Study completedNCT03819010What this trial is testingNeoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -Who this might be right forBreast Cancer MedSIR 66
Testing effectiveness (Phase 2)Looking for participantsNCT05770531What this trial is testingCirculating Tumor DNA to Guide Changes in Standard of Care ChemotherapyWho this might be right forMetastatic HER2-Negative Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma Vanderbilt-Ingram Cancer Center 160
Testing effectiveness (Phase 2)Looking for participantsNCT07616453What this trial is testingEfficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerWho this might be right forHR+/HER2- Early Breast Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine 45
Testing effectiveness (Phase 2)Study completedNCT01745965What this trial is testingA Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.Who this might be right forBreast Cancer Women's Cancer Study Group GmbH 380
Not applicableNot Yet RecruitingNCT07406594What this trial is testingGut Microbiome Changes During Abemaciclib Therapy in Breast CancerWho this might be right forBreast CancerHER-2 Positive Breast Cancer University of Vermont Medical Center 12
Not applicableStudy completedNCT01934478What this trial is testingRadiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast CancerWho this might be right forHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast Qingdao Central Hospital 5
Large-scale testing (Phase 3)Active Not RecruitingNCT05889390What this trial is testingNeoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast CancerWho this might be right forHER2-negative Breast Cancer Semmelweis University 71
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439110What this trial is testingTesting Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)Who this might be right forAdvanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more National Cancer Institute (NCI) 38
Early research (Phase 1)Looking for participantsNCT06084481What this trial is testingStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400Who this might be right forHepatocellular CarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract Cancers+5 more AbbVie 325
Not applicableEnded earlyNCT02963363What this trial is testingAdapted Physical Activity for Breast Cancer HER2 Positive PatientWho this might be right forHER2 Positive Breast Cancer Centre Jean Perrin 36
Not applicableStudy completedNCT03437837What this trial is testingValidation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in ChinaWho this might be right forBreast CancerNeoadjuvant TherapyNeoplasm Staging+5 more Peking University First Hospital 1,077
Testing effectiveness (Phase 2)Ended earlyNCT00864175What this trial is testingOpen Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast CancerWho this might be right forBreast Cancer Incyte Corporation 68
Testing effectiveness (Phase 2)Looking for participantsNCT07616427What this trial is testingFovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerWho this might be right forHR+/HER2+ Early Breast Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine 100